



SOURCE: DIAGNOS INC.

TSX Venture SYMBOL (TSX Venture Exchange): ADK

REPRICING OF WARRANTS APPROVED

Longueuil, Canada- October 3, 2003-Diagnos Inc. ("**Diagnos**" or the "**Corporation**") announced that the TSX Venture Exchange has approved the amendment of the exercise price of an aggregate 1,250,000 common share purchase warrants issued by the Corporation on December 27, 2001. The exercise price of the warrants will be reduced from \$0.60 to \$0.19 from the remainder of the term.

Pursuant to Exchange Policies, if the closing price for the Corporation's shares is \$0.24 or greater for a period of ten consecutive trading days then the holders of repriced warrants will have 30 days to exercise their warrants, otherwise their warrants will expire on the 31st day.

DIAGNOS Inc., develops and markets proprietary knowledge extraction solutions and tools that allow intelligent analysis of text, numerical and image databases.

The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Corporation's ongoing quarterly filings, annual reports and other filings for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.

-30-

For further information:

Christian Dufour

President, COO

Phone : (450) 678-8882, ext. 1,

E-mail: cdufour@diagnos.ca